OncLive
@onclive.bsky.social
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Martha Welman, MD, discusses findings from a study of resources used to reduce time to breast cancer screening and diagnosis. #bcsm
Stay tuned for more from the interview, only on our site! In the meantime, catch up on our coverage of #SABCS25: www.onclive.com/conference/s...
Stay tuned for more from the interview, only on our site! In the meantime, catch up on our coverage of #SABCS25: www.onclive.com/conference/s...
February 13, 2026 at 9:42 PM
Martha Welman, MD, discusses findings from a study of resources used to reduce time to breast cancer screening and diagnosis. #bcsm
Stay tuned for more from the interview, only on our site! In the meantime, catch up on our coverage of #SABCS25: www.onclive.com/conference/s...
Stay tuned for more from the interview, only on our site! In the meantime, catch up on our coverage of #SABCS25: www.onclive.com/conference/s...
👀 What presentations were most noteworthy from the #Tandem2026? Sign up to read insights from #hematology experts about research expected to propel cell therapy developments! @osucccjames.bsky.social @ohsunews.bsky.social @stanfordmedicine.bsky.social #Oncology
www.onclive.com/view/experts...
www.onclive.com/view/experts...
February 12, 2026 at 3:07 PM
👀 What presentations were most noteworthy from the #Tandem2026? Sign up to read insights from #hematology experts about research expected to propel cell therapy developments! @osucccjames.bsky.social @ohsunews.bsky.social @stanfordmedicine.bsky.social #Oncology
www.onclive.com/view/experts...
www.onclive.com/view/experts...
Watch 👀: Amrita Desai, MD, MPH of @ohsunews.bsky.social discusses lifileucel in metastatic melanoma at #Tandem26.
#melsm #oncology @astct.bsky.social @cibmtr.bsky.social
See the whole video here ➡️: onclive.com/shorts/tackl...
#melsm #oncology @astct.bsky.social @cibmtr.bsky.social
See the whole video here ➡️: onclive.com/shorts/tackl...
February 7, 2026 at 4:43 PM
Watch 👀: Amrita Desai, MD, MPH of @ohsunews.bsky.social discusses lifileucel in metastatic melanoma at #Tandem26.
#melsm #oncology @astct.bsky.social @cibmtr.bsky.social
See the whole video here ➡️: onclive.com/shorts/tackl...
#melsm #oncology @astct.bsky.social @cibmtr.bsky.social
See the whole video here ➡️: onclive.com/shorts/tackl...
Thanks to Dr Alfonso Molina, of @stanfordhealthcare.bsky.social, for joining us at #Tandem26 to share findings with Orca-T and allogeneic CAR-T cell therapy in B-ALL! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #leusm #hematology
www.onclive.com/conference/tct
www.onclive.com/conference/tct
February 7, 2026 at 2:00 AM
Thanks to Dr Alfonso Molina, of @stanfordhealthcare.bsky.social, for joining us at #Tandem26 to share findings with Orca-T and allogeneic CAR-T cell therapy in B-ALL! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #leusm #hematology
www.onclive.com/conference/tct
www.onclive.com/conference/tct
Thank you to Dr Amrita Desai, of @ohsunews.bsky.social, for stopping by during #Tandem26 to chat about real-world outcomes with lifileucel in melanoma! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #melsm
www.onclive.com/conference/tct
www.onclive.com/conference/tct
February 7, 2026 at 1:54 AM
Thank you to Dr Amrita Desai, of @ohsunews.bsky.social, for stopping by during #Tandem26 to chat about real-world outcomes with lifileucel in melanoma! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #melsm
www.onclive.com/conference/tct
www.onclive.com/conference/tct
A huge thanks to Dr Fernando Duarte, who sat down with us at #Tandem26 to discuss the use of allogeneic HCT in MDS in Brazil! Check out our site for more of today's exclusive meeting coverage! @astct.bsky.social @cibmtr.bsky.social #hematology
www.onclive.com/conference/tct
www.onclive.com/conference/tct
February 7, 2026 at 1:50 AM
A huge thanks to Dr Fernando Duarte, who sat down with us at #Tandem26 to discuss the use of allogeneic HCT in MDS in Brazil! Check out our site for more of today's exclusive meeting coverage! @astct.bsky.social @cibmtr.bsky.social #hematology
www.onclive.com/conference/tct
www.onclive.com/conference/tct
What do you bring with you to every conference❓
Check out how experts at #Tandem26 answered. 😂
@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology
Watch the whole video here ➡️: www.onclive.com/shorts/hemat...
Check out how experts at #Tandem26 answered. 😂
@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology
Watch the whole video here ➡️: www.onclive.com/shorts/hemat...
February 7, 2026 at 1:46 AM
What do you bring with you to every conference❓
Check out how experts at #Tandem26 answered. 😂
@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology
Watch the whole video here ➡️: www.onclive.com/shorts/hemat...
Check out how experts at #Tandem26 answered. 😂
@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology
Watch the whole video here ➡️: www.onclive.com/shorts/hemat...
Thank you to Dr Nathan Denlinger, of @osucccjames.bsky.social, for stopping by during #Tandem26 to talk about real-world data with CAR T-cell therapy in LBCL!
See our site for more from the meeting! @astct.bsky.social @cibmtr.bsky.social #lymsm #hematology
www.onclive.com/conference/tct
See our site for more from the meeting! @astct.bsky.social @cibmtr.bsky.social #lymsm #hematology
www.onclive.com/conference/tct
February 6, 2026 at 3:24 AM
Thank you to Dr Nathan Denlinger, of @osucccjames.bsky.social, for stopping by during #Tandem26 to talk about real-world data with CAR T-cell therapy in LBCL!
See our site for more from the meeting! @astct.bsky.social @cibmtr.bsky.social #lymsm #hematology
www.onclive.com/conference/tct
See our site for more from the meeting! @astct.bsky.social @cibmtr.bsky.social #lymsm #hematology
www.onclive.com/conference/tct
We have touched down in Salt Lake City for the 2026 Transplantation & Cellular Therapy Meetings! We're gearing up for lots of excitement on the ground for the first day of the meeting today, so stay tuned! @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #hematology
www.onclive.com/conference/tct
www.onclive.com/conference/tct
February 4, 2026 at 2:28 PM
We have touched down in Salt Lake City for the 2026 Transplantation & Cellular Therapy Meetings! We're gearing up for lots of excitement on the ground for the first day of the meeting today, so stay tuned! @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #hematology
www.onclive.com/conference/tct
www.onclive.com/conference/tct
As the 2026 Transplantation & Cellular Therapy Meetings approach, Drs Phillips, Dholaria, and Ahmed note the abstracts they’re watching. @astct.bsky.social @cibmtr.bsky.social
#Tandem2026 #leusm #hematology
👉 Sign up to read the full preview: www.onclive.com/view/hematol...
#Tandem2026 #leusm #hematology
👉 Sign up to read the full preview: www.onclive.com/view/hematol...
February 3, 2026 at 12:41 PM
As the 2026 Transplantation & Cellular Therapy Meetings approach, Drs Phillips, Dholaria, and Ahmed note the abstracts they’re watching. @astct.bsky.social @cibmtr.bsky.social
#Tandem2026 #leusm #hematology
👉 Sign up to read the full preview: www.onclive.com/view/hematol...
#Tandem2026 #leusm #hematology
👉 Sign up to read the full preview: www.onclive.com/view/hematol...
Rahul Banerjee, MD, FACP, discusses the implications of the FDA’s draft guidance on the use of minimal residual disease as a surrogate end point in clinical trials to support the accelerated approval of agents for the treatment of multiple myeloma #mmsm #oncology www.onclive.com/shorts/impli...
February 2, 2026 at 6:28 PM
Rahul Banerjee, MD, FACP, discusses the implications of the FDA’s draft guidance on the use of minimal residual disease as a surrogate end point in clinical trials to support the accelerated approval of agents for the treatment of multiple myeloma #mmsm #oncology www.onclive.com/shorts/impli...
Watch @erikahamilton9.bsky.social highlight key efficacy findings from the HER2CLIMB-05 trial of tucatinib plus trastuzumab and pertuzumab in HER2+ metastatic breast cancer. Check out our site for more #bcsm insights! #oncology
www.onclive.com/clinical/her...
www.onclive.com/clinical/her...
February 2, 2026 at 2:09 PM
Watch @erikahamilton9.bsky.social highlight key efficacy findings from the HER2CLIMB-05 trial of tucatinib plus trastuzumab and pertuzumab in HER2+ metastatic breast cancer. Check out our site for more #bcsm insights! #oncology
www.onclive.com/clinical/her...
www.onclive.com/clinical/her...
Dana Chase, MD, Maurie Markman, MD, and Robert Neff, MD, detail the current state of HPV vaccination and screening during #CervicalCancerAwarenessMonth
Sign up and read their exclusive insights #gynsm #oncology www.onclive.com/view/hpv-vac...
Sign up and read their exclusive insights #gynsm #oncology www.onclive.com/view/hpv-vac...
January 31, 2026 at 4:06 PM
Dana Chase, MD, Maurie Markman, MD, and Robert Neff, MD, detail the current state of HPV vaccination and screening during #CervicalCancerAwarenessMonth
Sign up and read their exclusive insights #gynsm #oncology www.onclive.com/view/hpv-vac...
Sign up and read their exclusive insights #gynsm #oncology www.onclive.com/view/hpv-vac...
Insights on the top 2025 oncology conference data, including Alexander Olawaiye, MD, and @drdanachase.bsky.social on gynecologic cancers; @balazshalmos.bsky.social on lung cancer; and John O. Mascarenhas, MD, on hematologic malignancies
Sign up & read more: www.onclive.com/view/2025-da...
Sign up & read more: www.onclive.com/view/2025-da...
January 30, 2026 at 9:52 PM
Insights on the top 2025 oncology conference data, including Alexander Olawaiye, MD, and @drdanachase.bsky.social on gynecologic cancers; @balazshalmos.bsky.social on lung cancer; and John O. Mascarenhas, MD, on hematologic malignancies
Sign up & read more: www.onclive.com/view/2025-da...
Sign up & read more: www.onclive.com/view/2025-da...
Thank you to Stacy Tessler Lindau, MD, MA, of @uchicagocancer.bsky.social for stopping by for an excellent interview detailing the ongoing bionic breast project! Check out onclive.com for clips from the interview. #oncology #bcsm
January 30, 2026 at 8:36 PM
Thank you to Stacy Tessler Lindau, MD, MA, of @uchicagocancer.bsky.social for stopping by for an excellent interview detailing the ongoing bionic breast project! Check out onclive.com for clips from the interview. #oncology #bcsm
Thank you to Alexandra Rojek, MD, of @uchicagocancer.bsky.social for participating in an interview which covered the evolving roles of CAR T-cell therapy and bispecifics in lymphoma! Check out our short on the topic which is live on onclive.com #oncology #hematology #CART #bispecifics
January 30, 2026 at 5:57 PM
Thank you to Alexandra Rojek, MD, of @uchicagocancer.bsky.social for participating in an interview which covered the evolving roles of CAR T-cell therapy and bispecifics in lymphoma! Check out our short on the topic which is live on onclive.com #oncology #hematology #CART #bispecifics
We are looking forward to our final day at @uchicagocancer.bsky.social We have some exciting interviews lined up covering clinical trials in breast cancer, the Bionic Breast project, and more! Stay tuned to onclive.com for all of our coverage. #oncology #bcsm #clinicaltrials
January 30, 2026 at 3:35 PM
We are looking forward to our final day at @uchicagocancer.bsky.social We have some exciting interviews lined up covering clinical trials in breast cancer, the Bionic Breast project, and more! Stay tuned to onclive.com for all of our coverage. #oncology #bcsm #clinicaltrials
Molecularly driven therapies highlight ongoing research in MPNs @mountsinainyc.bsky.social
www.onclive.com/shorts/molec...
www.onclive.com/shorts/molec...
January 30, 2026 at 3:32 PM
Molecularly driven therapies highlight ongoing research in MPNs @mountsinainyc.bsky.social
www.onclive.com/shorts/molec...
www.onclive.com/shorts/molec...
Alexandra Rojek, MD, of @uchicagocancer.bsky.social stopped by for an interview to discuss the exciting future of CAR T-cell therapy and bispecifics in lymphoma care. Check out www.onclive.com for highlights of the conversation. #oncology #hematology #CART #lymphoma
January 29, 2026 at 9:29 PM
Alexandra Rojek, MD, of @uchicagocancer.bsky.social stopped by for an interview to discuss the exciting future of CAR T-cell therapy and bispecifics in lymphoma care. Check out www.onclive.com for highlights of the conversation. #oncology #hematology #CART #lymphoma
Thank you to Alex Pearson, MD, of @uchicagocancer.bsky.social for an excellent conversation on the evolving role of AI in oncology! Be sure to watch onclive.com for the highlights of the discussion. #oncology #medtwitter #AI
January 29, 2026 at 7:42 PM
Thank you to Alex Pearson, MD, of @uchicagocancer.bsky.social for an excellent conversation on the evolving role of AI in oncology! Be sure to watch onclive.com for the highlights of the discussion. #oncology #medtwitter #AI
A huge thank you to Sonali Smith, MD, of @uchicagocancer.bsky.social for stopping by for an interview covering advances in CAR T-cell therapy and the role of clinical trials in cancer care. Check out onclive.com for clips from the interview and an upcoming podcast episode! #oncology #hematology
January 29, 2026 at 5:59 PM
A huge thank you to Sonali Smith, MD, of @uchicagocancer.bsky.social for stopping by for an interview covering advances in CAR T-cell therapy and the role of clinical trials in cancer care. Check out onclive.com for clips from the interview and an upcoming podcast episode! #oncology #hematology
We are excited to be on-site today at @uchicagocancer.bsky.social with some exciting interviews lined up with experts spanning topics including clinical trials, advances in CAR T-cell therapy, AI in oncology, and more! Stay tuned to onclive.com for our coverage. #oncology #AI #CART #hematology
January 29, 2026 at 3:23 PM
We are excited to be on-site today at @uchicagocancer.bsky.social with some exciting interviews lined up with experts spanning topics including clinical trials, advances in CAR T-cell therapy, AI in oncology, and more! Stay tuned to onclive.com for our coverage. #oncology #AI #CART #hematology
BREAKING 🚨: @fda.gov Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL #lymsm #leusm
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
January 28, 2026 at 2:18 PM
BREAKING 🚨: @fda.gov Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL #lymsm #leusm
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
BREAKING 🚨: @fda.gov Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma #mmsm #Oncology
Learn more 📰: onclive.com/view/fda-app...
Learn more 📰: onclive.com/view/fda-app...
January 27, 2026 at 7:55 PM
BREAKING 🚨: @fda.gov Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma #mmsm #Oncology
Learn more 📰: onclive.com/view/fda-app...
Learn more 📰: onclive.com/view/fda-app...
Watch Pooja Phull, MD, discuss the implications of a study showing how butyrate loss may affect post-transplant outcomes in patients with multiple myeloma. And check out our site for more insights from Dr Phull! #mmsm #hematology
www.onclive.com/view/microbi...
www.onclive.com/view/microbi...
January 23, 2026 at 11:04 PM
Watch Pooja Phull, MD, discuss the implications of a study showing how butyrate loss may affect post-transplant outcomes in patients with multiple myeloma. And check out our site for more insights from Dr Phull! #mmsm #hematology
www.onclive.com/view/microbi...
www.onclive.com/view/microbi...